Efficacy and safety of cryoablation combined with lenvatinib and anti-PD-1 monoclonal antibody in treatment of unresectable hepatocellular carcinoma / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 539-549, 2024.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-1013134
Responsible library:
WPRO
ABSTRACT
ObjectiveTo investigate whether anti-PD-1 monoclonal antibody can improve the efficacy and safety of cryoablation combined with lenvatinib in the treatment of unresectable hepatocellular carcinoma (HCC). MethodsA retrospective analysis was performed for 232 patients with unresectable HCC who were treated at The Fifth Medical Center of Chinese PLA General Hospital from January 2018 to December 2022, among whom 128 received cryoablation combined with lenvatinib (double combination) and 104 received cryoablation combined with lenvatinib and anti-PD-1 monoclonal antibody (triple combination). Propensity score matching was performed at a ratio of 1∶1, and finally there were 86 patients in each group. The two groups were evaluated in terms of objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs). The independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. Survival curves were plotted, and the Kaplan-Meier method was used to calculate the survival rate of patients in both groups, while the log-rank test was used for comparison between the two groups. The Cox regression model was used to calculate hazard ratio (HR) and 95% confidence interval (CI) and perform the univariate and multivariate analyses of influencing factors for prognosis. ResultsThe median follow-up time was 28 months, and there were 33 deaths (38.0%) in the triple combination group and 40 deaths (46.0%) in the double combination group. Compared with the double combination group, the triple combination group had significantly higher ORR (35.6% vs 14.5%, P=0.008) and DCR (86.1% vs 64.1%, P=0.003). OS and PFS in the triple combination group were significantly higher than those in the double combination group (P=0.045 and 0.026). The univariate and multivariate Cox proportional-hazards regression model analyses showed that treatment regimen (HR=0.60, P=0.038) and alpha-fetoprotein level (HR=2.37, P=0.001) were independent risk factors for OS, and treatment regimen (HR=0.65, P=0.025), diabetes mellitus (HR=1.94, P=0.005), whether or not to have received local treatment (HR=0.63, P=0.014), and distant metastasis (HR=0.58, P=0.009) were independent risk factors for PFS. There was no significant difference in the incidence rate of AEs between the two groups (P>0.05). ConclusionFor patients with unresectable HCC, the triple combination of cryoablation, lenvatinib, and anti-PD-1 monoclonal antibody significantly improves the treatment outcome and survival of patients compared with the double combination of cryoablation and lenvatinib, without increasing AEs, which provides a clinical basis for optimizing the treatment regimen for unresectable HCC.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Clinical Hepatology
Year:
2024
Document type:
Article